Nikhil C. Munshi: Getting MRD as an endpoint was a great partnership between academia and industry and patient organization

Nikhil C. Munshi, Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, shared a post on X:

“Getting Minimal Residual Disease (MRD) as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner.”